SUSMED vs IBTR Risk Estimation

SUSMEDはサスメド株式会社が開発した研究用アプリです。 本アプリの使用には、研究への参加が必要です。 本アプリを使用することで、臨床研究ごとに設定された情報を入力いただき、研究参加者と研究実施者による効率的な研究実施をサポートします。 SUSMEDアプリを使用した臨床研究への参加者には、研究実施者による説明の後、ログインのためのアカウントが発行されます。 使用の条件や個人情報等の扱いについては、研究実施者が提供する説明を参照ください。

This application is a tool to estimate the risk of ipsilateral breast tumor recurrence (IBTR) after breast-conserving surgery. It provides 10-year IBTR risk estimates and treatment effects, based on clinicopathological factors (age, pathological T stage, grade, margin status, lymphovascular invasion, hormone receptor status, HER2 status) and treatment options (radiation therapy, chemotherapy, endocrine therapy, anti-HER2 therapy). The application is available for both iPhone and iPad. The tool was developed using a Cox proportional hazards model from a multicenter cohort of 8,938 patients and calibrated with treatment effects from the EBCTCG meta-analysis. It is designed for use in shared decision-making between patients and clinicians, as well as for educational purposes. The development methodology was presented at the 2025 ASCO Annual Meeting (Abstract No. 575) and published in JCO Clinical Cancer Informatics (Sagara et al., 2025). For further details, please refer to the publication. Disclaimer This application is intended for educational and informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Clinical decisions should always be made in consultation with the treating physician. The developers assume no legal responsibility for any outcomes resulting from the use of this application.